Statement of Principles concerning malignant neoplasm of the eye (Reasonable Hypothesis) (No. 27 of 2018)

The SOP structures entitlement risk around a threshold evidentiary device described as a "reasonable hypothesis" connecting disease (or death) to relevant service (s 8-9). Main concepts and mechanisms in the instrument are:

• Definition of the injury or disease: "malignant neoplasm of the eye" is confined to primary malignancies of the eyeball and conjunctiva and enumerates included subtypes and exclusions (s 7(2)-(4)). The instrument clarifies anatomical limits (note following s 7(2)) such as exclusion of extraocular muscles, optic nerve, orbital contents, eyelid skin, Meibomian glands and lacrimal apparatus.

• Reasonable hypothesis as a binary evidential gate: the SOP identifies specific causative or contributory "factors" any one of which, when shown and linked to relevant service, suffices to raise the reasonable hypothesis required for entitlement consideration (s 9). The instrument lists discrete, measurable thresholds,hours, treatment counts, durations, timing windows,rather than open-ended causal language.

• Relationship to "relevant service": the factor(s) relied on must be related to the person's relevant service as defined in the Dictionary, which includes various forms of operational, peacekeeping, hazardous, British nuclear test defence service under the VEA and warlike or non‑warlike service under the MRCA (Schedule 1). Section 10(1) requires the factor's existence to be related to relevant service; s 10(2) restricts the "inability to obtain appropriate clinical management" factor to material contribution/aggravation cases where the disease was suffered or contracted before or during (but not arising out of) service.

• Disease- and exposure‑specific thresholds: different oncological subtypes have their own triggering factors and thresholds. Examples include PUVA whole‑body therapy counts (200 treatments and first treatment at least 10 years before onset for melanoma, s 9(7)(a)); at least two episodes of photokeratitis, with first at least five years before onset for melanoma (s 9(7)(b)); UV-emitting tanning device exposures on ten occasions with first at least five years before onset (s 9(2)); welding exposure (manual welding equipment) for at least ten cumulative years for uveal melanoma (s 9(6)(a)); and voriconazole continuous treatment for at least four weeks before clinical onset for squamous cell carcinoma (s 9(9)(c)).

• Quantification of sunlight exposure across latitudes: the SOP provides a method to compute "equivalent sunlight exposure" using a latitude weighting factor schedule in Schedule 1. The schedule assigns weighting factors of 1.0, 0.75, 0.5 and 0.25 to progressively higher latitude bands; the claimant must demonstrate cumulative hours equivalent to 2,250 hours in a tropical area, or the calculated equivalent across zones (s 9(1); Schedule 1).

• Cross-application and reliance on other SOPs: where a listed factor refers to an injury or disease covered by another SOP, the terms of that other SOP apply (s 11). The instrument therefore operates within a broader SOP ecosystem and can import standards from other statements.

• Temporal rules for causation and cessation: several factors require specific temporal relationships between exposure/treatment and clinical onset,minimum latencies, cumulative exposures prior to onset, and post-cessation windows in which onset must occur (e.g., immunosuppressive drug exposure requirements in s 9(4)).

These concepts convert clinical and occupational histories into administrable thresholds for use in statutory entitlement assessments. The SOP favours specific, documentable facts (hours, counts, dates, diagnoses and treatments) rather than amorphous causal narratives.

Primary groups affected by this SOP are claimants under the VEA and MRCA seeking service‑related liability for malignant neoplasm of the eye (s 5), their treating clinicians, occupational and military record‑keepers, and decision‑makers who apply SOPs in administrative determinations. The SOP's reach touches the following actors and activities:

• Veterans, current/former members of Peacekeeping Forces and members of the Forces whose service history includes operational, peacekeeping, hazardous or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA. For any such person with malignant neoplasm of the eye or death from it, the SOP prescribes the evidential factors that can raise a reasonable hypothesis connecting the disease to their relevant service (s 5; Schedule 1 definitions of "relevant service" and MRCA/VEA).

• Medical practitioners: ophthalmologists, dermatologists, oncologists and general practitioners will be asked to provide clinical diagnoses that fit the SOP's definitional framework (s 7), to identify date of clinical onset and histopathological confirmation of specific subtypes (for example, squamous cell carcinoma or uveal melanoma), and to document treatments (PUVA counts, voriconazole duration, immunosuppressive drug courses, transplantation events). The SOP sets precise clinical criteria and timing windows that clinicians must address in reports.

• Occupational and service record custodians: establishing factors such as cumulative sunlight/UV exposure by latitude, manual welding employment for ten years, PCB exposure frequency, tanning‑device visitation counts, or whole‑body PUVA treatment counts requires historical records. Military duty stations, operational theatres, trade employment records and medical/clinic treatment registers will be relevant. The latitude weighting schedule in Schedule 1 requires location and exposure hours per latitude zone.

• Administrators and adjudicators: decision‑makers assessing claims under s 120A VEA or s 338 MRCA will use the SOP as an evidentiary and causal framework. The SOP narrows what evidence can suffice to raise a reasonable hypothesis and therefore affects the preliminary acceptance or rejection of claims.

• Third parties and experts: medico‑legal experts, occupational hygienists and historians may be engaged to quantify exposures, calculate equivalent hours using the Schedule 1 weighting factors, and relate such exposures to specific periods of relevant service.

• Claim outcomes and beneficiaries: if a reasonable hypothesis is raised in accordance with this SOP and the decision‑maker accepts the claim under the relevant Act, the claimant may receive benefits or compensation as provided by the VEA or MRCA. The SOP therefore influences allocation of public resources tied to service‑related disease liabilities.

Notably, the SOP does not itself create new obligations for private entities beyond record provision in customary processes, nor does it impose sanctions on employers or clinicians. It does, however, change how claimants must marshal evidence to meet the "reasonable hypothesis" standard: the instrument privileges measurable, time‑bounded exposures and clinical data (s 9, Schedule 1). Where a factor references another SOP's injury or disease, the claimant must comply with the terms of that other SOP as in force (s 11).

The SOP does not itself impose statutory duties, criminal sanctions, or private rights of action. Instead, it prescribes evidential and definitional rules that govern administrative entitlement decisions under the VEA and MRCA. The operative duties and rights arising indirectly from the instrument are:

• Duty of proof at the "reasonable hypothesis" threshold: claimants must establish at least one of the factors listed in s 9, and that the factor is related to their relevant service (s 9, s 10(1)). The presence of any one qualifying factor meeting the SOP's thresholds is the minimum needed to "raise" a reasonable hypothesis; the SOP thereby sets a gate for administrative consideration.

• Right to have the SOP applied to eligible claims: the instrument expressly applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). Claimants within that scope have the right to have their claim assessed using this SOP as the relevant evidentiary instrument.

• Duty to show temporally compliant exposures and clinical onset: many factors in s 9 include timing requirements such as minimum latency between first exposure/treatment and clinical onset, cumulative exposure duration thresholds, and windows after cessation in which onset must occur (see s 9(1)-(11)). Claimants must adduce records or credible evidence to meet those temporal conditions; medical reports should specify the date of clinical onset.

• Duty to provide clinical and exposure documentation: to prove factors like immunosuppressive drug exposure, transplantation, PUVA counts, voriconazole continuous treatment, tanning device exposures, welding history, PCB exposure frequency, HPV infection with specified types, ocular prosthesis duration, or inability to obtain appropriate clinical management, claimants will need supporting medical records, pharmacy records, surgical/transplantation logs, employment records, or specialist statements. The SOP functions as a checklist of documentary proof required to meet the reasonable hypothesis standard.

• Right to cross-application of other SOPs: if a factor in this SOP refers to an injury or disease covered by another SOP, the claimant has the right to rely on that other SOP’s factors in accordance with its terms as in force (s 11). This creates a procedural right to consolidation of standards where factors overlap.

• Right to have definition interpreted according to the instrument: the SOP’s definition of malignant neoplasm of the eye (s 7(2)-(4)) prevails over a mere reliance on ICD-10‑AM codes, although the instrument notes the usual ICD codes for the condition (s 7(3)-(4)). That is, entitlement assessments must use the SOP’s textual definition rather than relying only on code mappings.

• Duty to relate factors to relevant service: the SOP requires that any established factor be shown to be connected to the individual's relevant service (s 10(1)). For the special factor in s 9(11) (inability to obtain appropriate clinical management), s 10(2) narrows application to material contribution or aggravation where the disease pre‑existed or was contracted before or during (but not arising out of) service.

The SOP does not specify procedural rights such as appeal or review within the instrument itself. Those rights and duties are provided by the VEA and MRCA and implementing administrative processes. The SOP therefore functions as a substantive evidentiary template that shapes what proof decision‑makers will treat as sufficient to meet the statutory "reasonable hypothesis" gateway for service connection.

The Statement of Principles instrument contains no criminal or civil penalties and does not include enforcement mechanisms in the traditional regulatory sense. It is a subordinate legislative instrument under the VEA intended to guide administrative determinations about service connection for malignant neoplasm of the eye (s 3, s 5). Consequently:

• No penal sanctions in the SOP text: the instrument’s provisions set medical and evidential thresholds (s 7-11, Schedule 1) but do not prescribe fines, imprisonment or other penalties for non‑compliance by individuals or organisations. The instrument does not create offences.

• Administrative enforcement is the practical mechanism: enforcement of the SOP’s thresholds occurs through administrative decision‑making processes under the VEA and MRCA. Decision‑makers will accept or reject claims in reliance on whether the claimant establishes one or more of the factors listed and their relationship to relevant service (s 9-10). The SOP is a legal standard used to decide entitlement, but the instrument itself does not describe adjudicative or review processes; those are governed by the primary Acts.

• Evidentiary consequence rather than sanction: the "enforcement effect" is consequential,if a claimant cannot demonstrate any qualifying factor related to relevant service according to the SOP, a "reasonable hypothesis" will not be raised and the claim may be dismissed or denied under the VEA or MRCA. Conversely, demonstrating a qualifying factor may require the decision‑maker to accept service connection until contrary evidence is decisive. The SOP sets the minimal factual gateway for administrative acceptance.

• Interaction with other administrative law remedies: while not described in this instrument, administrative decisions under the VEA and MRCA are subject to statutory review and appeal mechanisms that exist in those Acts and associated procedures. The SOP will be a relevant subordinate instrument that tribunals and courts (where applicable) may consider when reviewing administrative decisions. The SOP itself contains no guidance on how tribunals should weigh competing evidence; it supplies the threshold conditions to be met.

• Revocation and amendment as instruments of control: the RMA may revoke or amend SOPs, as this instrument revokes the prior No. 15 of 2010 (s 4) and has itself been amended (see endnotes). Such revocation or amendment changes the evidential framework for future claims and can have retroactive or prospective application depending on governing transitional provisions in the primary Acts and any amendment instruments.

In summary, the SOP's "enforcement" role is to structure administrative determinations by specifying what factors and proof will constitute a reasonable hypothesis of service connection. It does not create prosecutorial or penal processes; compliance is assessed by decision‑makers under the VEA and MRCA using the SOP as an evidential template.

The SOP explicitly situates itself within the statutory architecture of the VEA and MRCA and interfaces with external classification systems and other Statements of Principles. The instrument refers to and must be read in the context of several legal and administrative instruments:

• Made under the VEA: the SOP is determined under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s 3). Its legal force is as a subordinate instrument for use in determinations under the VEA and, by application, under the MRCA where specified (s 5). Decision‑makers applying the SOP do so within the statutory frameworks and procedures provided by those Acts.

• Applies to specific claim‑types under primary Acts: it applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). Those sections of the parent Acts set out how service connection and the "reasonable hypothesis" threshold operate; this SOP supplies the medical factors used to operationalise that threshold for malignant neoplasm of the eye.

• Interaction with other SOPs: s 11 provides a directed interaction: where a factor in this SOP refers to an injury or disease covered by another SOP determined under subsection 196B(2) of the VEA, then the factors in that other SOP apply in accordance with its terms as in force. This creates a legal mechanism for consistency and cross‑reference among SOPs rather than isolated, potentially conflicting standards.

• Use of ICD-10-AM and copyright considerations: s 7(3)-(4) acknowledges that the condition normally attracts specific ICD‑10‑AM codes (C69.x, D09.2) but clarifies that for application of this SOP the statutory meaning is the textual definition in s 7(2). The instrument also identifies the specific edition of ICD‑10‑AM cited and states its copyright attribution (s 7(4)). This means that while codings are noted, entitlement hinges on the SOP's textual definitional limits.

• Definition importation from Schedule 1: technical terms used in the SOP draw their meanings from Schedule 1 , for example, "relevant service", "tropical area", "unprotected eye", "whole body PUVA", "specified HPV", and "immunosuppressive drug". That makes Schedule 1 an integral part of the instrument and binds users to the precise statutory definitions when interacting with other laws or claims processes.

• No explicit interaction with workers' compensation, public health acts, or criminal law: the SOP does not reference other federal, state or territory statutes such as workers' compensation schemes or public health legislation. That said, decisions made under the VEA and MRCA that rely on the SOP could overlap factually with other statutory schemes, but the instrument itself provides no mechanism for cross‑claim coordination.

• Administrative law and review: although not described in the SOP, it will be applied within adjudicative processes that are themselves subject to administrative law principles, statutory appeals and judicial review. The SOP’s status as a subordinate instrument and the RMA’s statutory role (s 3) suggests it will be treated as authoritative in administrative determinations. Where a factor invokes another SOP, the other SOP’s terms apply, which can affect the outcome of appeals or reviews.

Overall, the instrument establishes a technical evidentiary interface between medical facts and statutory definitions supplied by the VEA and MRCA, with cross-references to other SOPs and to the ICD classification system. It does not create rights or obligations under other, external statutes but acts as a binding technical tool for decision‑makers within the veterans' entitlements framework.

The compilation records and endnotes included with the instrument disclose its amendment and revocation history. Key points from the instrument and the endnotes are:

• Original determination and commencement: the Statement of Principles concerning malignant neoplasm of the eye (Reasonable Hypothesis) (No. 27 of 2018) was registered on 5 March 2018 (F2018L00196) and commenced on 2 April 2018 (Endnote 3 table; s 2). The instrument bears the Repatriation Medical Authority's date of determination of 2 March 2018.

• Revocation of earlier SOP: the instrument expressly revokes the prior Statement of Principles concerning malignant neoplasm of the eye No. 15 of 2010 (s 4). The revocation replaces the earlier SOP with this text as the operative standard from commencement.

• Amendment No. 19 of 2020: the compilation includes amendments up to Amendment Statement of Principles concerning malignant neoplasm of the eye (Reasonable Hypothesis) (No. 19 of 2020) (F2020L00198). That amendment instrument is registered 2 March 2020 and has a day of commencement of 23 March 2020 (Endnote 3). Endnote 4 records that Clause 9(4) and the Schedule 1 Dictionary entry for "immunosuppressive drug" were revised by No. 19 of 2020 (Endnote 4 table).

• Effect of amendments shown in the current text: the current text of s 9(4) specifies an immunosuppressive drug exposure pattern with a cumulative treatment period of at least three months before clinical onset, first treatment at least five years before clinical onset, and if exposure ceased, onset that occurs within ten years of cessation (s 9(4)(a)-(c)). Schedule 1 now defines "immunosuppressive drug" and lists illustrative examples including chemotherapeutic agents, systemic corticosteroids (excluding inhaled or topical forms), drugs used to prevent transplant rejection, and tumour necrosis factor-α inhibitors (Schedule 1). Endnote 4 shows these were subject to the 2020 amendment.

• Compilation dating and scope: the compilation notes its compilation date as 23 March 2020 and indicates that it includes amendments up to No. 19 of 2020 (the amendment instrument with commencement 23 March 2020). The endnotes explain that any amendments not commenced by compilation date are not shown in the compiled text and provide references to the Legislation Register for uncommenced amendments.

• Nature of amendment entries: endnotes classify changes at the provision level. For this instrument the recorded amendments indicate targeted changes rather than wholesale restructuring: s 9(4) and Schedule 1’s immunosuppressive drug definition were the specific loci of change.

Practically, amendments to the SOP alter the evidential and medical thresholds used in compensation decisions. The 2020 changes to immunosuppression‑related factors and the drug definition affect how certain immunosuppressive treatment histories will be assessed for the "reasonable hypothesis" gateway for malignant neoplasm of the eye. The instrument’s endnotes provide the formal amendment trail and registration details necessary for legal citation and for understanding the version of the SOP in force at a given time.

The instrument as compiled contains no internal record of judicial or tribunal decisions addressing its validity or application. The compilation’s endnotes list legislation and amendment history but do not record any litigation relating to this Statement of Principles (Endnote 3 and Endnote 4). Therefore, within the four corners of this document:

• No cases are named: the SOP does not cite or summarise judicial or tribunal decisions that interpret or challenge its provisions. The instrument is a technical subordinate instrument produced by the Repatriation Medical Authority; any litigation that may arise from application of the SOP would be recorded in judicial or tribunal databases and not in the SOP text itself.

• Administrative review and appeal processes are external: any challenge to a decision applying this SOP would proceed through the appeal and review mechanisms provided by the VEA and MRCA (for example, merits review bodies or courts), but the SOP itself does not outline or document such proceedings.

• Implication for practitioners: absence of litigation history in the text means that users must seek case law and tribunal decisions in external legal databases to determine how courts or review bodies have interpreted "reasonable hypothesis", the quantification of exposure, calculation of equivalent sunlight using the latitude weighting schedule, or the application of timing windows for factors such as immunosuppressive drug exposures and PUVA counts. The SOP should be treated as an authoritative technical fixture within the administrative framework; interpretation questions will be resolved in the administrative decision and any subsequent review or judicial forum.

• Practical consequence: because the SOP establishes specific, numerically defined thresholds (e.g., 2,250 cumulative hours in tropical areas; ten tanning device occasions; 200 whole body PUVA treatments for melanoma), litigation that does occur will likely focus on evidentiary sufficiency, the reliability of exposure reconstructions, and the legal construction of "related to relevant service" under s 10(1), rather than on the underlying medical associations the SOP asserts (which are the rationale for the RMA’s determination per s 8).

In short, the instrument’s text and endnotes do not record litigation. Practitioners must consult tribunal and court reporting systems for precedents addressing application of this SOP in specific claims.

This SOP contains numerous technical thresholds and definitional constraints that create practical pitfalls for claimants, clinicians and decision‑makers. Highlighted potential "gotchas" grounded in the instrument are:

• Strict anatomical and primary‑tumour limitation: s 7(2) confines coverage to primary malignant neoplasms arising from eyeball and conjunctiva tissue and explicitly excludes retinoblastoma, sarcomas of connective tissue and bone, lymphomas (non‑Hodgkin’s and Hodgkin’s), carcinoid tumours and secondary/metastatic lesions by implication. A claimant whose tumour is on excluded tissues or is metastatic to the eye will not meet this SOP’s definitional threshold even if clinically severe.

• ICD codes not determinative: although s 7(3) lists ICD‑10‑AM codes that malignant neoplasm of the eye typically attracts, the SOP’s operative meaning is the textual definition in s 7(2). Relying solely on an ICD code without addressing the SOP’s anatomical and histological definitions risks rejection.

• Calculation complexity for sunlight exposure: s 9(1) requires cumulative sunlight/UV exposure of at least 2,250 hours while in a tropical area or equivalent exposure calculated using the Schedule 1 latitude weighting factor schedule. This requires a claimant to reconstruct exposure hours by location and multiply by the appropriate weighting factor for each latitude zone (Schedule 1). Military records or civilian employment logs must show locations and time‑on‑duty or recreational exposure, and calculation errors or insufficient granularity in records can defeat a claim.

• "Unprotected eye" standard: several factors (s 9(2), s 9(7)(a), s 9(9)(b)) specify exposure to the "unprotected eye". Schedule 1 defines "unprotected eye" as an eye not protected by UV‑screening devices such as goggles. Records that do not document whether protective eyewear was used, or which infer intermittent protection, may be insufficient to meet the SOP standard.

• Differing thresholds by subtype: the SOP segments factors by tumour subtype. For example, PUVA thresholds for melanoma require 200 whole‑body treatments with first treatment at least 10 years before onset (s 9(7)(a)), while squamous cell carcinoma requires only 25 PUVA treatments with first treatment at least five years before onset (s 9(9)(b)). Confusing these counts or failing to specify whether PUVA was whole‑body (as distinct from localised) can lead to incorrect application.

• Temporal latency and cessation windows: several factors include minimum latency before clinical onset (e.g., tanning device exposures at least five years before onset, s 9(2); first PUVA for melanoma at least 10 years before onset, s 9(7)(a)) or windows after cessation for onset to occur (e.g., s 9(4)(c) , onset within ten years of cessation of immunosuppressive drug exposure). Claims that lack clear documentation of treatment start and stop dates, or that show onset outside specified windows, will fail to meet the SOP thresholds.

• Evidence scarcity for recreational exposures: tanning‑device exposure requirements (s 9(2)) demand proof of at least ten occasions of unprotected exposure at least five years before onset. Tanning salon records are not always preserved and personal recollection may be insufficient. Similarly, proving cumulative sunlight exposure hours for varied postings or leave periods is evidentially demanding.

• Occupational exposure quantification: welding exposure for uveal melanoma requires manual welding equipment use for a cumulative period of at least ten years (s 9(6)(a)). Employment histories or trade registration may indicate welding roles but may not quantify hours or establish that welding was manual rather than automated, which can be decisive.

• PCB exposure frequency and duration: s 9(6)(b) requires exposure to transformer or capacitor oils containing polychlorinated biphenyls on average at least two times per month for a cumulative period of at least ten years. Establishing both frequency and PCB presence in oils used historically may be challenging, particularly where records are incomplete or chemical composition statements are unavailable.

• Viral typing requirement for HPV: for squamous cell carcinoma, s 9(9)(a) requires persistent infection of conjunctival epithelium with "specified human papilloma virus (HPV)" types (Schedule 1 lists types 5, 8, 14, 16 or 18). General documentation of HPV infection without type specification will not meet this factor.

• Voriconazole and pharmaceutical timing specifics: s 9(9)(c) requires continuous voriconazole treatment for at least four weeks before clinical onset. Shorter courses or interrupted therapy, or lack of pharmacy records, will be insufficient.

• Ocular prosthesis duration: s 9(10) requires an ocular prosthesis in an anophthalmic socket for more than ten years before clinical onset. Precise surgical or prosthetic fitting dates are therefore material.

• Narrow application of "inability to obtain appropriate clinical management": s 9(11) and s 10(2) limit this factor to situations where the claimant’s malignant neoplasm of the eye was suffered or contracted before or during (but did not arise out of) relevant service and where inability to obtain management materially contributed to or aggravated the condition. This is a constrained remedy for situations of absent treatment and will not apply where the disease arises out of service.

• Cross‑SOP dependency: s 11 requires deference to other SOPs where factors reference diseases covered elsewhere. Practitioners must identify and review any referenced SOPs, including their own amendments and definitions, to ensure consistent application.

These points are mechanical and documentary. The SOP transforms clinical and occupational facts into administrable triggers. Practitioners must pay careful attention to the instrument’s numeric thresholds, timing windows, and definitions to avoid evidential failures.

Complying with the SOP for a claim requires assembling a factual and medical record that maps directly onto the instrument’s listed factors, timing windows and definitions. Practical steps grounded in the text are:

1. Confirm the diagnosis and subtype under the SOP definition

   • Obtain and compile ophthalmological and histopathology reports that identify the tumour as a primary malignant neoplasm of the eyeball or conjunctiva and, where relevant, specify subtype (uveal melanoma, conjunctival melanoma, squamous cell carcinoma of cornea or conjunctiva, or melanoma in situ) (s 7(2)(a)-(b)).
   • Ensure the diagnosis excludes the instrument’s excluded conditions (retinoblastoma, sarcomas, lymphomas, carcinoid), and document the anatomical boundaries noted in the SOP (note following s 7(2)).

2. Establish the date of clinical onset

   • Secure clinical notes, imaging, pathology and specialist letters that identify the date of clinical onset; many factors require calculation of latency relative to that onset date (s 9 generally).

3. Identify which factor(s) a claimant can legitimately rely upon

   • Map available evidence against the enumerated factors in s 9. Do not rely on a generic causal argument: at least one listed factor must exist and be connected to relevant service (s 9; s 10(1)).

4. Gather documentary proof for the chosen factor(s)

   • Sunlight/UV exposure (s 9(1)): collect military posting location records, employment rosters, duty rosters, leave and deployment records, and personal statements that identify hours spent outdoors by location. Use the latitude weighting factor schedule (Schedule 1) to convert hours by zone into equivalent tropical hours; prepare a traceable calculation showing hours, zone multipliers and totals.
   • Tanning device exposure (s 9(2)): obtain salon records where available, dated receipts, photographs, or contemporaneous diary entries that document at least ten unprotected exposure occasions with dates at least five years before clinical onset.
   • Immunosuppressive drug exposure (s 9(4)): compile pharmacy dispensing records, hospital and specialist letters indicating drug names, start/stop dates, cumulative duration of systemic immunosuppressive therapy (minimum three months), date of first treatment (must be at least five years before onset), and if therapy ceased, demonstration that clinical onset occurred within ten years of cessation. Use Schedule 1’s "immunosuppressive drug" definition and examples to explain the drug class.
   • Transplantation (s 9(5)): obtain transplant operation records, discharge summaries, and immunosuppression protocols showing transplantation date before clinical onset.
   • Occupation exposures (s 9(6)(a) welding; s 9(6)(b) PCBs): secure trade or employment records, employer declarations, pay records, technical descriptions of job tasks, and any records indicating exposure to transformer or capacitor oils with PCB content; produce calculations of exposure frequency (two times per month average) and cumulative duration (ten years).
   • PUVA therapy (s 9(7)(a), s 9(9)(b)): obtain dermatology or hospital treatment logs showing the number of whole‑body PUVA treatments, dates of first treatment and total counts to meet the 200 or 25 treatment thresholds as applicable, and confirm whether treatments were whole‑body (Schedule 1 excludes localised PUVA).
   • Photokeratitis episodes (s 9(7)(b)): obtain ophthalmology or emergency department records documenting photokeratitis episodes and dates, and ensure the first occurred at least five years prior to onset.
   • HPV typing (s 9(9)(a)): secure microbiology or pathology reports identifying persistent infection of the conjunctival epithelium and specifying HPV type(s) among types 5, 8, 14, 16 or 18.
   • Voriconazole treatment (s 9(9)(c)): obtain pharmacy dispensing or hospital records confirming continuous voriconazole treatment for at least four weeks before clinical onset.
   • Ocular prosthesis (s 9(10)): obtain surgical and prosthetic fitting records showing implantation date and that an ocular prosthesis was present in an anophthalmic socket for more than ten years before onset.
   • Inability to obtain appropriate clinical management (s 9(11), s 10(2)): gather contemporaneous medical records showing antecedent disease presence before or during service, attempts to obtain treatment, service region health infrastructure documentation, and evidence linking lack of management to material contribution or aggravation of disease. Remember this factor is narrowly confined to disease present before or during service (s 10(2)).

5. Link the established factor(s) to relevant service

   • Demonstrate the relationship required by s 10(1): show that the factor (for example, exposure location or occupational task) is temporally and causally connected to the person’s relevant service as defined in Schedule 1. For exposures that occurred both in service and outside, specify which portion is attributable to relevant service.

6. Prepare medico‑legal or expert evidence where necessary

   • Consider obtaining an expert report that reconstructs exposures, explains how quantitative thresholds are met, applies the latitude weighting calculation for sunlight exposure and addresses causation in the context of the specific factor and timing requirements of the SOP.

7. Cross‑reference other SOPs

   • If a chosen factor implicates another SOP (s 11), obtain and review that SOP and align proofs to the other SOP’s requirements to ensure consistent application.

8. Ensure documentary chain and calculations are auditable

   • Where numerical thresholds are decisive (hours, counts, durations, frequency), provide source documents and a worked calculation. For sunlight exposure, include the hours by date and location and the latitude weighting math as required by Schedule 1.

9. Anticipate evidentiary weaknesses and prepare alternative factors

   • If a primary factor is weak (for example, tanning device occasions), identify alternative factors from s 9 that could be supported by different evidence streams (immunosuppression, transplantation, occupation) and prepare supporting documentation.

10. Keep versions and amendment dates in mind

• Use the version of the SOP in force at the time the decision is made. Note that this instrument replaced No. 15 of 2010 and was amended by No. 19 of 2020 (Endnotes). Ensure that the factual window and definitions used in submissions correspond to the SOP version relied upon.

Following these steps will align a claim file with the SOP’s mechanistic requirements. The SOP is prescriptive: satisfying the enumerated factor(s) and their relationship to relevant service (s 9-10) is the minimal legal threshold to raise a reasonable hypothesis of service connection; claims should therefore be assembled with a focus on precise dates, counts, and documentary sources that the instrument itself specifies.